Search Results - "Sue, D"

Factors Used to Determine Return to Unrestricted Sports Activities After Anterior Cruciate Ligament Reconstruction by Barber-Westin, Sue D., B.S, Noyes, Frank R., M.D

“…Purpose Anterior cruciate ligament (ACL) reconstruction is commonly performed in athletes, with the goal of return to sports activities. Unfortunately, this…”
Get full text

Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial by Davies, Melanie, Færch, Louise, Jeppesen, Ole K, Pakseresht, Arash, Pedersen, Sue D, Perreault, Leigh, Rosenstock, Julio, Shimomura, Iichiro, Viljoen, Adie, Wadden, Thomas A, Lingvay, Ildiko

“…This trial assessed the efficacy and safety of the GLP-1 analogue once a week subcutaneous semaglutide 2·4 mg versus semaglutide 1·0 mg (the dose approved for…”
Get full text

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes by Husain, Mansoor, Birkenfeld, Andreas L, Donsmark, Morten, Dungan, Kathleen, Eliaschewitz, Freddy G, Franco, Denise R, Jeppesen, Ole K, Lingvay, Ildiko, Mosenzon, Ofri, Pedersen, Sue D, Tack, Cees J, Thomsen, Mette, Vilsbøll, Tina, Warren, Mark L, Bain, Stephen C

“…Safety data exist for subcutaneous semaglutide, a glucagon-like peptide-1 receptor agonist, but not for the oral form. Here, oral semaglutide was assessed in a…”
Get full text

Metabolic complications of obesity by Pedersen, Sue D., Dr

“…Obesity is a risk factor for several metabolic complications, with insulin resistance being the common denominator in these conditions. Impaired blood glucose…”
Get full text

Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial by O'Neil, Patrick M, Birkenfeld, Andreas L, McGowan, Barbara, Mosenzon, Ofri, Pedersen, Sue D, Wharton, Sean, Carson, Charlotte Giwercman, Jepsen, Cecilie Heerdegen, Kabisch, Maria, Wilding, John P H

“…Obesity is a major public health issue, and new pharmaceuticals for weight management are needed. Therefore, we evaluated the efficacy and safety of the…”
Get full text

Effect of Fatigue Protocols on Lower Limb Neuromuscular Function and Implications for Anterior Cruciate Ligament Injury Prevention Training: A Systematic Review by Barber-Westin, Sue D., Noyes, Frank R.

“…Background: Approximately two-thirds of anterior cruciate ligament (ACL) tears are sustained during noncontact situations when an athlete is cutting, pivoting,…”
Get full text

Clinical Healing Rates of Meniscus Repairs of Tears in the Central-Third (Red-White) Zone by Barber-Westin, Sue D., B.S, Noyes, Frank R., M.D

“…Purpose To determine the clinical healing rate of repairs of meniscus tears that extend into the central one-third region and the factors that affect the…”
Get full text

Long-term Survivorship and Function of Meniscus Transplantation by Noyes, Frank R., Barber-Westin, Sue D.

“…Background: Clinical outcomes and survivorship of meniscus transplants remain unclear, especially when magnetic resonance imaging (MRI) and weightbearing…”
Get full text

Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial by Frias, Juan P, Deenadayalan, Srikanth, Erichsen, Lars, Knop, Filip K, Lingvay, Ildiko, Macura, Stanislava, Mathieu, Chantal, Pedersen, Sue D, Davies, Melanie

“…Combining the GLP-1 receptor agonist semaglutide with the long-acting amylin analogue cagrilintide has weight-loss benefits; the impact on glycated haemoglobin…”
Get full text

Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial by Garvey, W Timothy, Birkenfeld, Andreas L, Dicker, Dror, Mingrone, Geltrude, Pedersen, Sue D, Satylganova, Altynai, Skovgaard, Dorthe, Sugimoto, Danny, Jensen, Camilla, Mosenzon, Ofri

“…Most individuals with type 2 diabetes also have obesity, and treatment with some diabetes medications, including insulin, can cause further weight gain. No…”
Get full text

Efficacy and safety of once-daily oral semaglutide 25 mg and 50 mg compared with 14 mg in adults with type 2 diabetes (PIONEER PLUS): a multicentre, randomised, phase 3b trial by Aroda, Vanita R, Aberle, Jens, Bardtrum, Lars, Christiansen, Erik, Knop, Filip K, Gabery, Sanaz, Pedersen, Sue D, Buse, John B

“…Once-daily oral semaglutide is an effective type 2 diabetes treatment. We aimed to investigate a new formulation of oral semaglutide at higher investigational…”
Get full text

Treatment of Meniscus Tears During Anterior Cruciate Ligament Reconstruction by Noyes, Frank R., M.D, Barber-Westin, Sue D., B.S

“…Purpose To define the incidence of meniscectomy, meniscus repair, and meniscus tears left in situ during anterior cruciate ligament (ACL) reconstruction…”
Get full text

Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial by Lau, David C W, Erichsen, Lars, Francisco, Ann Marie, Satylganova, Altynai, le Roux, Carel W, McGowan, Barbara, Pedersen, Sue D, Pietiläinen, Kirsi H, Rubino, Domenica, Batterham, Rachel L

“…Natural amylin is a pancreatic hormone that induces satiety. Cagrilintide is a long-acting amylin analogue under investigation for weight management. We…”
Get full text

Toxoplasma gondii infections are associated with costly boldness toward felids in a wild host by Gering, Eben, Laubach, Zachary M., Weber, Patty Sue D., Soboll Hussey, Gisela, Lehmann, Kenna D. S., Montgomery, Tracy M., Turner, Julie W., Perng, Wei, Pioon, Malit O., Holekamp, Kay E., Getty, Thomas

“…Toxoplasma gondii is hypothesized to manipulate the behavior of warm-blooded hosts to promote trophic transmission into the parasite’s definitive feline hosts…”
Get full text

Blood Flow Restriction Training Can Improve Peak Torque Strength in Chronic Atrophic Postoperative Quadriceps and Hamstrings Muscles by Noyes, Frank R., Barber-Westin, Sue D., Sipes, Lindsey

“…To report a prospective study of patients who underwent blood flow restriction training (BFRT) for marked quadriceps or hamstring muscle deficits after failure…”
Get full text

Effects of PYY3-36 and GLP-1 on energy intake, energy expenditure, and appetite in overweight men by Schmidt, Julie Berg, Gregersen, Nikolaj Ture, Pedersen, Sue D, Arentoft, Johanne L, Ritz, Christian, Schwartz, Thue W, Holst, Jens Juul, Astrup, Arne, Sjödin, Anders

“…Our aim was to examine the effects of GLP-1 and PYY3-36, separately and in combination, on energy intake, energy expenditure, appetite sensations, glucose and…”
Get more information

Relationship between body weight change and glycaemic control with tirzepatide treatment in people with type 2 diabetes: A post hoc assessment of the SURPASS clinical trial programme by Pedersen, Sue D., Giorgino, Francesco, Umpierrez, Guillermo, Thieu, Vivian T., Rodríguez, Angel, Nicolay, Claudia, Fernández Landó, Laura, Karanikas, Chrisanthi A., Kiljanski, Jacek

“…Aim To assess the relationship between HbA1c and body weight reductions with tirzepatide treatment (5, 10 or 15 mg). Materials and Methods HbA1c and body…”
Get full text

Neuromuscular Retraining Intervention Programs: Do They Reduce Noncontact Anterior Cruciate Ligament Injury Rates in Adolescent Female Athletes? by Noyes, Frank R., M.D, Barber-Westin, Sue D., B.S

“…Purpose The purpose of this study was to identify neuromuscular training intervention programs that significantly reduced the incidence of noncontact anterior…”
Get full text

Gastrointestinal tolerability of once‐weekly semaglutide 2.4 mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss by Wharton, Sean, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Goldman, Bryan, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Thomsen, Mette, Wadden, Thomas A., Pedersen, Sue D.

“…Aim We evaluated gastrointestinal (GI) adverse events (AEs) with once‐weekly semaglutide 2.4 mg in adults with overweight or obesity and their contribution to…”
Get full text

Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice by Wharton, Sean, Davies, Melanie, Dicker, Dror, Lingvay, Ildiko, Mosenzon, Ofri, Rubino, Domenica M., Pedersen, Sue D.

“…Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are well established in clinical practice for the treatment of type 2 diabetes, and are approved and…”
Get full text